The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $44.25

Today's change+0.09 +0.20%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $44.25

Today's change+0.09 +0.20%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Abbott Laboratories up (U.S.)$0.09

Abbott Laboratories closed up Wednesday by (U.S.)$0.09 or 0.20% to (U.S.)$44.25. Over the last five days, shares have gained 1.89% and are currently 1.16% off of the 52-week high. Shares have performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $44.16
  • Previous close(U.S.) $44.16
  • High(U.S.) $44.43
  • Low(U.S.) $43.99
  • Bid / Ask-- / --
  • YTD % change+15.44%
  • Volume2,876,740
  • Average volume (10-day)4,474,480
  • Average volume (1-month)4,415,080
  • Average volume (3-month)4,852,216
  • 52-week range(U.S.) $35.65 to (U.S.) $44.77
  • Beta0.61
  • Trailing P/E40.54×
  • P/E 1 year forward19.55×
  • Forward PEG2.22×
  • Indicated annual dividend(U.S.) $0.88
  • Dividend yield1.99%
  • Trailing EPS(U.S.) $1.09
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+8.14%

Based on its net profit margin of 8.14%, Abbott Laboratories is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.77%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue5,1045,5515,2445,655
Total other revenue--------
Total revenue5,1045,5515,2445,655
Gross profit2,7783,0482,7793,095
Total cost of revenue2,3262,5032,4652,560
Total operating expense4,3734,7904,7934,899
Selling / general / administrative1,5661,7371,7391,654
Research & development305335387386
Depreciation / amortization132161174198
Interest expense (income), net operating--------
Unusual expense (income)44512582
Other operating expenses, total--------
Operating income731761451756
Interest income (expense), net non-operating-35---49--
Gain (loss) on sale of assets--------
Other--------
Income before tax718737423737
Income after tax440460339589
Income tax, total27827784148
Net income538466375590
Total adjustments to net income--------
Net income before extra. items440460339589
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items440460339589
Inc. avail. to common incl. extra. items538466375590
Diluted net income538466375590
Dilution adjustment--0----
Diluted weighted average shares1,5201,5171,5481,567
Diluted EPS excluding extraordinary itemsvalue per share0.290.300.220.38
Dividends per sharevalue per share0.220.220.220.14
Diluted normalized EPSvalue per share0.310.320.230.42